Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell entities : In8bio inc save search
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 6.42%
H: 1.72%
C: -5.17%
cell preclinical for therapy platform
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 0.83%
H: 5.79%
C: -7.44%
publication cell immunology therapy glioblastoma
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Published: 2023-10-12 (Crawled : 12:00) - globenewswire.com
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 1.0%
H: 0.0%
C: -5.94%
inb-100 inb-400 cell treatment trial potential therapy glioblastoma
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 3.36%
H: 3.25%
C: -6.5%
day cell city research
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
Published: 2023-05-17 (Crawled : 12:00) - globenewswire.com
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 0.37%
H: 5.33%
C: 3.73%
cancer promise show
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023
Published: 2023-04-24 (Crawled : 14:00) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 140.95%
H: 56.12%
C: 18.58%
inb-100 leukemia
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
Published: 2022-12-08 (Crawled : 13:20) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 0.81%
H: 2.01%
C: -6.02%
inb-400 fda clearance trial phase 2 glioblastoma
IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400
Published: 2022-09-15 (Crawled : 12:00) - globenewswire.com
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: -3.68%
H: 8.78%
C: 5.34%
inb-400 t-cell program
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Published: 2022-03-28 (Crawled : 18:00) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 1.2%
H: 0.0%
C: -3.85%
inb-100 ongoing leukemia trial therapy t-cell phase 1
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 4.66%
H: 2.34%
C: 2.34%
genetic trial cel phase 1 therapy t-cell glioblastoma
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Published: 2021-12-16 (Crawled : 13:30) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 3.96%
H: 8.32%
C: -4.51%
ema ongoing leukemia trial cel stem cell phase 1 therapy t-cell
IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors
Published: 2021-11-11 (Crawled : 14:00) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: -3.04%
H: 7.24%
C: -1.81%
solid tumors potential therapy t-cell preclinical pre-clinical
IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
Published: 2021-10-27 (Crawled : 12:15) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 0.37%
H: 3.05%
C: -7.81%
results preclinical t-cell pre-clinical glioblastoma
IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Published: 2021-08-11 (Crawled : 14:00) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: 5.4%
H: 0.0%
C: -4.45%
stem cell phase 1 therapy leukemia trial t-cell
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.